Ticker Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.

Aditya Birla Money Limited

Aditya Birla Money Limited

Haleos Labs Limited

Symbol : HALEOSLABS | BSE Code : 540679 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

1,287.7033.90 (2.70%)
02-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

389.31
Today’s High / Low
1,290.00
1,197.60
52 Week High / Low
1,680.00
1,029.05
1,299.0045.20 (3.61%)
02-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

392.72
Today’s High / Low
1,299.00
1,299.00
52 Week High / Low
1,680.00
1,050.05
1,287.7033.90 (2.70%)
02-Apr-2026 | 12:00

Turnover (₹ Cr.)

82,717,186,200.00
Today’s High / Low
51,993
50,172.00
1,287.7033.90 (2.70%)
02-Apr-2026 | 12:00

Turnover (₹ Cr.)

0.00
Today’s High / Low
0
0.00
OVERVIEW
  • Open
  • 1,197.60
  • Prev. Close
  • 1,253.80
  • High
  • 1,290.00
  • Low
  • 1,197.60
  • Market Cap (₹ Cr.)
  • 389.31
  • 52 Week High
  • 1,680.00
  • 52 Week Low
  • 1,029.05
  • Traded Volume (Lacs)
  • 603
  • Traded Value (Cr)
  • Dividend Yield
  • 0.12
  • Face Value
  • 10.00
  • EPS
  • 60.26
  • P/E
  • 21.56
  • Beta (1 year)
  • 1.02
OVERVIEW
  • Open
  • 1,299.00
  • Prev. Close
  • 1,253.80
  • High
  • 1,299.00
  • Low
  • 1,299.00
  • Market Cap (₹ Cr.)
  • 392.72
  • 52 Week High
  • 1,680.00
  • 52 Week Low
  • 1,050.05
  • Traded Volume (Lacs)
  • 1
  • Traded Value (Cr)
  • Dividend Yield
  • 0.12
  • Face Value
  • 10.00
  • EPS
  • 60.26
  • P/E
  • 21.56
  • Beta (1 year)
OVERVIEW
  • Open
  • 50,760.00
  • Prev. Close
  • 51,784.60
  • High
  • 51,993
  • Low
  • 50,172.00
  • Strike Price
  • 0.00
  • Open Interest(Nos.)
  • 2,472,210.00
  • OI Change %
  • 3.30
  • Volume(Lacs)
  • 3.30
  • Lot Size
  • 30.00
  • Average Price
  • 50,944.43
  • OI Difference
  • 79,080.00
  • Previous OI
  • 2,393,130.00
OVERVIEW
  • Open
  • 0.00
  • Prev. Close
  • 1,940.00
  • High
  • 0
  • Low
  • 0.00
  • Strike Price
  • 24,950.00
  • Open Interest(Nos.)
  • 2,860.00
  • OI Change %
  • 0.00
  • Volume(Lacs)
  • 0.00
  • Lot Size
  • 65.00
  • Average Price
  • 0.00
  • OI Difference
  • 0.00
  • Previous OI
  • 2,860.00
LAST 5 DAYS

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY -11.66%

  • 04/04/2026 BSE
    45.20(3.61)
    Close Price: ₹ 1,299.00
    Volume: 1.00

    02-Apr-2026
  • 04/04/2026 BSE
    54.40(4.54)
    Close Price: ₹ 1,253.80
    Volume: 1.00

    01-Apr-2026
  • 04/04/2026 BSE
    -50.60(-4.05)
    Close Price: ₹ 1,199.40
    Volume: 17.00

    30-Mar-2026
  • 04/04/2026 BSE
    12.30(0.99)
    Close Price: ₹ 1,250.00
    Volume: 10,001.00

    27-Mar-2026
  • 04/04/2026 BSE
    -57.60(-4.45)
    Close Price: ₹ 1,237.70
    Volume: 108.00

    25-Mar-2026

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY -11.66%

  • Stock Absolute
  • 3.92
  • 1.88
  • 7.36
  • 150.99
  • 163.84
  • Returns
  • 1W
  • 1M
  • 1Y
  • 3Y
  • 5Y
  • Sensex Absolute
  • -0.36
  • -8.62
  • -4.30
  • 24.05
  • 49.15
NEWS

Haleos Labs consolidated net profit rises 21.02% in the December 2025 quarter

12-Feb-2026

No Data Available

Net profit of Haleos Labs rose 21.02% to Rs 6.62 crore in the quarter ended December 2025 as against Rs 5.47 crore during the previous quarter ended December 2024. Sales rose 12.03% to Rs 94.78 crore in the quarter ended December 2025 as against Rs 84.60 crore during the previous quarter ended December 2024.

ParticularsQuarter Ended
Dec. 2025Dec. 2024% Var.
Sales94.7884.60 12
OPM %14.8215.07 -
PBDT12.6910.67 19
PBT8.786.92 27
NP6.625.47 21

12
Feb

Haleos Labs consolidated net profit rises 21.02% in the December 2025 quarter



05
Feb

Haleos labs to convene board meeting



11
Nov

SMS Lifesciences India consolidated net profit rises 30.62% in the September 2025 quarter



FINANCIAL DATA

In Cr.

Mar 2025Mar 2024Mar 2023
SOURCES OF FUNDS :   
Share Capital 3.023.023.02
Reserves Total 194.15173.20161.00
Equity Share Warrants0.000.000.00
Equity Application Money0.000.000.00
Read More
Mar 2025Mar 2024Mar 2023
INCOME :   
Sales Turnover 368.35328.75351.88
Excise Duty34.9828.7536.63
Net Sales333.37300.00315.25
Other Income 3.953.845.23
Read More
ParticularsDec 2025Sep 2025Jun 2025
Gross Sales 80.7277.8479.04
Excise Duty 000
Net Sales 80.7277.8479.04
Other Operating Income 000
Other Income  0.080.441.01
Read More
Category No. Of Shares Percentage (%)
Total Foreign 7156 0.24
Total Institutions 8782 0.29
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 92530 3.06
Total Promoters 2170576 71.80
Total Public & others 744,243.00 24.62
Total 100.00 100.00
Read More
CORPORATE ACTIONS
Record Date Ex-Bonus Date Ratio
nodata
No Data Available!!!
Read More
Record Date Split Date Face Value Before Face Value After
nodata
No Data Available!!!
Read More
Read More
ANNOUNCEMENT DATE EX DIVIDEND DATE DIVIDEND (%) DIVIDEND TYPE
29-05-2025 24-09-2025 15 Final
27-05-2024 23-09-2024 15 Final
29-05-2023 22-09-2023 15 Final
28-05-2022 22-09-2022 15 Final
18-06-2021 20-09-2021 15 Final
PREMIUM (₹) RATIO RECORD DATE EX RIGHTS DATE
nodata
No Data Available!!!
Read More
Read More
FROM DATE EX TO DATE AGENDA
29-04-2026 01-05-2026 Enclosed - Outcome of 96th Boa...
05-03-2026 NA TV Praveen
11-02-2026 NA Quarterly Results Haleos La...
26-12-2025 NA TV Praveen
24-12-2025 NA TV Praveen
COMPANY INFO

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006. The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016.

The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.

Having three multi product facilities in operation and a research centre, the Company executed contract manufacturing and research assignment for global customer base. The Scheme of Arrangement between SMS Pharmaceuticals Limited with the Company was implemented in 2016-17. Pursuant to the Scheme, the Semi Regulated facilities i.e Unit No. I, IV and V along with premises situated at Industrial Estate, Sanathnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19.00 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units of SMS Pharmaceuticals Limited got demerged into the Company and the said Scheme of Demerger was given effect on May 17, 2017. The Company allotted 30,23,287 Equity Shares of Rs. 10 each to the shareholders of SMS Pharmaceuticals Limited on 27 June, 2017 in pursuance of Demerg

Read More
Get Free Demat Account
Captcha Image